Cite
HARVARD Citation
Xu, Z. et al. (n.d.). Nivolumab provides improved effectiveness and safety compared with docetaxel as a second‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis. Cancer medicine. pp. 629-642. [Online].